Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply
- PMID: 37314719
- DOI: 10.1056/NEJMc2304782
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply
Comment on
-
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources